# Junta clínica — PT-pseudo_c13fda040310 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c13fda040310",
  "pid": "PT-pseudo_c13fda040310",
  "task": 1,
  "psa": 6.1,
  "age": 63,
  "months": 3,
  "pirads": "4",
  "psad": 0.08,
  "psav": 1.35,
  "psap": 4.9,
  "vol": 73.0,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.81674135,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin",
  "notes": "PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 73 mL. csPCa 0.82.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "81 kg",
    "height": "180 cm",
    "bmi": "25.0",
    "bp": "125/95 mmHg",
    "hr": "72 bpm",
    "smoking": "Current smoker (23 pack-yr)",
    "last_dental": "6 mo ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "19 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "An escalating PSA trajectory reaching 6.1 ng/mL after a previously negative systematic biopsy necessitates specialist re-evaluation."
    },
    {
      "s": "History",
      "t": "Divorced and currently residing with a partner, the 63-year-old freelance translator entered initial prostate cancer risk assessment in mid-2023 following a PSA reading of 3.5 ng/mL. Over the subsequent two years, he has experienced a steady, asymptomatic PSA increase now reaching 6.1 ng/mL. Despite the earlier negative biopsy, he expresses considerable apprehension regarding another invasive procedure. Lower urinary tract symptoms remain minimal (IPSS 5), adequately controlled with tamsulosin and a routine of commuter cycling five times each week. His clinical background includes benign prostatic hyperplasia, well-managed type 2 diabetes treated with metformin and empagliflozin, as well as hypercholesterolaemia addressed through atorvastatin, simvastatin, and rosuvastatin. He maintains an active lifestyle despite being a current smoker with a 23 pack-year history. He explicitly denies haematuria, pelvic pain, or unexplained weight loss. A stable, decades-long right knee osteoarthritis restricts his marathon goals and occasionally requires paracetamol PRN. Weekly alcohol intake averages one unit, and he notes that extended hours spent translating technical documents frequently contribute to his general fatigue."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: none. The prostate is symmetrically enlarged but otherwise unremarkable, confirming a normal digital rectal examination. General physical assessment shows no abnormalities, with clear cardiovascular and respiratory auscultation, absent peripheral lymphadenopathy, and no palpable abdominal masses."
    }
  ],
  "occupation": "freelance translator",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [],
  "alcohol": "1 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 5/35 (mild LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "Catharina Ziekenhuis (Eindhoven)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c13fda040310
Task: 1

Encounter: Urology - outpatient on 19 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 6.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.35 ng/mL/yr
  - Prior PSA: 4.9 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81674135 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 73 mL. csPCa 0.82.

Vitals: weight 81 kg, height 180 cm, BMI 25.0, BP 125/95 mmHg, HR 72 bpm. Smoking: Current smoker (23 pack-yr).

Chief complaint: An escalating PSA trajectory reaching 6.1 ng/mL after a previously negative systematic biopsy necessitates specialist re-evaluation.

History: Divorced and currently residing with a partner, the 63-year-old freelance translator entered initial prostate cancer risk assessment in mid-2023 following a PSA reading of 3.5 ng/mL. Over the subsequent two years, he has experienced a steady, asymptomatic PSA increase now reaching 6.1 ng/mL. Despite the earlier negative biopsy, he expresses considerable apprehension regarding another invasive procedure. Lower urinary tract symptoms remain minimal (IPSS 5), adequately controlled with tamsulosin and a routine of commuter cycling five times each week. His clinical background includes benign prostatic hyperplasia, well-managed type 2 diabetes treated with metformin and empagliflozin, as well as hypercholesterolaemia addressed through atorvastatin, simvastatin, and rosuvastatin. He maintains an active lifestyle despite being a current smoker with a 23 pack-year history. He explicitly denies haematuria, pelvic pain, or unexplained weight loss. A stable, decades-long right knee osteoarthritis restricts his marathon goals and occasionally requires paracetamol PRN. Weekly alcohol intake averages one unit, and he notes that extended hours spent translating technical documents frequently contribute to his general fatigue.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: none. The prostate is symmetrically enlarged but otherwise unremarkable, confirming a normal digital rectal examination. General physical assessment shows no abnormalities, with clear cardiovascular and respiratory auscultation, absent peripheral lymphadenopathy, and no palpable abdominal masses.

Patient info: freelance translator; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 1 units / week; exercise Cycling 5x/week (commuter); IPSS score: 5/35 (mild LUTS).


Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.82
  uncertainty  +/- 0.10 epistemic (95% band 0.62-1.00); among patients I cannot tell apart the outcome was 0.68 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers BIOPSY.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 18 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 4, PSA 6.1, PSAD 0.08, age 63, DRE Normal -> BIOPSY (borderline). He wrote: "Rising PSA + PIRADS≥4 (limited size lesion) gives high probability of undetected prostate cancer. Therefore re-biopsy indicated. However, prev benign biopsy carries low…"
  2. distance 0.59: PI-RADS 4, PSA 6.0, PSAD 0.08, age 67, DRE Normal -> BIOPSY (clear). He wrote: "P4 lesion in 67 year old patient."
  3. distance 1.58: PI-RADS 4, PSA 9.2, PSAD 0.16, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Again earlier MRI report is missing, If new PRADS 4 lesion biopsy is needed as PSA is rising as well"

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: fh=important, pirads=important, dre=important, bx=important, psad=important, vol=noted, psa=important, age=important, cspca=important, comorbidity=noted.
HOW SURE HE USUALLY IS: borderline.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that the decision to perform a repeat biopsy after a negative systematic biopsy depends on several factors, including the MRI findings and PSA density. "Repeat biopsy after negative biopsy During follow-up after a negative systematic biopsy, the incidence of PCa is higher, but the risk of PCa death is lower than the population average [474]. Men with prior negative systematic biopsy and persistent suspicion of PCa should have an MRI if one has not already been performed."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled by the guideline because the guideline emphasizes that the decision depends on MRI findings and PSA density, which are not explicitly detailed as the deciding factor in the guideline excerpt. Expert 4's focus on the list of documents is secondary to the guideline's requirement to assess specific clinical and imaging parameters.

WHAT WE STILL NEED
The guideline requires assessment of the PSA density to guide the decision.
PSA density is 0.08 ng/mL², which falls below the 0.15 ng/mL/cc cut-off mentioned in the search results.
The guideline requires knowing if a repeat biopsy is indicated based on the PI-RADS score and PSA density, which is not explicitly established by the retrieved text alone.
The prior biopsy status is negative, which is a known fact on the panel.
The PSA value is 6.1 ng/mL, which is a known fact on the panel.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the clinical significance of the PI-RADS 4 finding in the context of the low PSA density, as per the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 4 lesion?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values beyond the headline value of 6.1 ng/mL?
  previous_notes (get_previous_notes) -> What was the GRADE (Gleason/ISUP) of the prior negative biopsy, and is a surveillance protocol in place?
  laboratory_results (get_lab_results) -> What is the full panel including free-PSA fraction, renal function, and haemoglobin?

On the plan itself: Dropped 2 question(s) that asked for a value already printed on the panel: "What is the specific interpretation of the PI-RADS 4 finding in relation to the EAU guideline requirements for repeat biopsy after a negative systematic biopsy?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone of the PI-RADS 4 lesion is approximately "12 x 9 x 11 mm" in the left mid-gland posterior peripheral zone.
psa_trend
The trend of the serial PSA values beyond the headline value of 6.1 ng/mL is: {"date": "Jun 2023", "val": 1.4}, {"date": "Jan 2024", "val": 2.3}, {"date": "Aug 2024", "val": 3.7}, {"date": "Feb 2025", "val": 6.1}.
previous_notes
The GRADE (Gleason/ISUP) of the prior negative biopsy was "entirely benign, with no signs of malignancy", and there is "not recorded" for a surveillance protocol.
laboratory_results
The full panel including free-PSA fraction is: PSA "6.1 ng/mL" on "04 Feb 2025", Free PSA "1.30 ng/mL" on "04 Feb 2025", "%Free PSA" "21%" on "04 Feb 2025", Haemoglobin "15.1 g/dL" on "04 Feb 2025", WBC "5.5 x10^9/L" on "04 Feb 2025", Platelets "201 x10^9/L" on "04 Feb 2025", Creatinine "98 umol/L" on "04 Feb 2025", eGFR ">60 mL/min/1.73m2" on "04 Feb 2025", Testosterone "11.3 nmol/L" on "04 Feb 2025", Alkaline phosphatase "74 U/L" on "04 Feb 2025", LDH "226 U/L" on "04 Feb 2025".

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not required to answer the specific questions posed by the moderator.

WHAT THIS SUPPORTS
FOR sampling this patient now:
PI-RADS score of 4 on the mpMRI.
Rising PSA trajectory from 3.5 ng/mL in June 2023 to 6.1 ng/mL in February 2025.
The EAU guideline notes that PSA density (0.08 ng/mL²) falls below the 0.15 ng/mL/cc cut-off.

AGAINST sampling this patient now:
Prior biopsy was negative.
The prior biopsy result was "entirely benign, with no signs of malignancy".

WHERE THIS LEANS
The findings suggest a need for further investigation due to the PI-RADS 4 finding and rising PSA, but the low PSA density presents a conflicting factor against immediate biopsy based on the EAU excerpt.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.10 ng/mL over 4 points spanning 20 months; velocity +2.75 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 9.4 ng/mL, conformal 95% band 2.7-32.6.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.83
  uncertainty  +/- 0.10 epistemic (95% band 0.63-1.00), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.82  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.83  ('firm' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (identical panel in the series)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_4)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: borderline. Weights it expects: fh=important, pirads=important, dre=important, bx=important, psad=important, vol=noted, psa=important, age=important, cspca=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—appear to address the core variables weighed by the trace model.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of BIOPSY, as the rising PSA trajectory and the PI-RADS 4 finding align with the cohort criterion.

THE OPEN QUESTIONS, ONE BY ONE
There were no open questions posed by the moderator to be answered by the registrar.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 4 is highly important as it is a primary driver for the cohort criterion. The rising PSA trajectory is also significant as it indicates disease progression. The prior negative biopsy result is a counterpoint, but the clinical context suggests further investigation is warranted.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, leaning towards a firm recommendation based on the convergence of the PI-RADS score and the PSA trend, despite the conflicting prior negative biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

Given the PI-RADS 4 finding on the MRI and the rising PSA trajectory from 3.5 ng/mL to 6.1 ng/mL, further investigation is warranted despite the prior negative biopsy. The low PSA density of 0.08 ng/mL² introduces a conflicting factor against immediate biopsy based on some guidelines. The evidence converged on the need for further investigation due to the PI-RADS 4 and PSA trend, leading to a recommendation for biopsy.

What carried weight: pirads=important, dre=important, bx=important, psad=important, vol=noted, psa=important, age=important, cspca=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
